Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 30 December 2011 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) released Friday a new draft guidance titled, Use of Histology in Biomarker Qualification Studies.
The document outlines the processes that industry should use to ensure histology data is accurate, sound, and adheres to scientific standards for biomarker characterization and qualification.
The FDA is hoping to provide clarity to the biomarker development process to spur successful product development, as outlined in its Critical Path Initiative. Biomarkers broadly apply to the molecular structure, biochemical measurements, and organ system functions of the body.
The guidance notes that, "if a biomarker becomes qualified, analytically valid measurements of it can be relied upon to have a specific and interpretable meaning in drug development and regulatory decision-making." This would be mutually beneficial to both the FDA and to industry in speeding up the development time and premarket review of the substance.
The Federal Register posting for the draft guidance also notes that the draft guidance is aimed at reducing the instances of unqualified biomarkers, which "can do considerable harm" to the drug development process by promoting an "erroneous perception of safety" and an inadequate risk-benefit profile that is unlikely to be approved by the FDA.
Tags: Qualification Studies, Histology, Latest News, biomarkers, draft guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.